Bharat Biotech has developed India’s first vaccine candidate for Covid-19, Covaxin, in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV).
The Drug Controller General of India- CDSCO and Ministry of Health & Family Welfare have granted permission for the Hyderabad-based company to initiate Phase I & II human clinical trials which are scheduled to start across India in July.
“We are proud to announce Covaxin, India’s first indigenous vaccine against Covid-19,’’ Krishna Ella, Chairman and Managing Director, Bharat Biotech, said in a release issued here on Monday.
The collaboration with ICMR and NIV was instrumental in the development of this vaccine. The proactive support and guidance from CDSCO have enabled approvals to this project, he added.
The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to the Hyderabad-based Bharat Biotech. The indigenous, inactivated vaccine developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad, India.
Bharat Biotech’s has so far developed several vaccines for polio, rabies, rotavirus, Japanese encephalitis, chikungunya and zika.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.